Long non-coding RNA ANRIL enhances mitochondrial function of hepatocellular carcinoma by regulating the...

Area of Science:

• Molecular Biology
• Oncology
• Biochemistry

Background:

• Long non-coding RNA (lncRNA) ANRIL (Antisense non-coding RNA in the INK4A locus) is implicated in various cancers.
• The role of ANRIL in mitochondrial metabolic reprogramming in hepatocellular carcinoma (HCC) remains largely unknown.

Purpose of the Study:

• To investigate the function of lncRNA ANRIL in regulating mitochondrial metabolic reprogramming in liver cancer cells.
• To elucidate the underlying molecular mechanism of ANRIL's action in HCC.

Main Methods:

• Quantitative real-time PCR to assess ANRIL expression in HCC tissues and cells.
• Functional experiments including overexpression and knockdown of ANRIL.
• Assessment of mitochondrial function markers: mitochondrial DNA copy number, ATP level, mitochondrial membrane potential, and mitochondrial marker expression.
• RNA immunoprecipitation and luciferase reporter assays to confirm the interaction between ANRIL, miR-199a-5p, and ARL2 (ADP-ribosylationfactor-like 2).

Main Results:

• ANRIL expression was significantly upregulated in HCC tissues and cells compared to normal controls.
• Overexpression of ANRIL enhanced mitochondrial function in HCC cells, while ANRIL knockdown impaired it.
• ANRIL functions as a competing endogenous RNA by sponging miR-199a-5p, leading to increased ARL2 expression.
• The ANRIL-miR-199a-5p-ARL2 axis was identified as crucial for ANRIL-mediated promotion of mitochondrial function in HCC cells.

Conclusions:

• lncRNA ANRIL plays a significant role in promoting HCC cell mitochondrial function and progression.
• A novel regulatory axis, ANRIL-miR-199a-5p-ARL2, is identified in HCC.
• This axis represents a potential therapeutic target for hepatocellular carcinoma treatment.